Notice of Results

RNS Number : 1241T

Oncimmune Holdings PLC

10 October 2017

 

10 October 2017

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Notice of Full Year Results

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, will be announcing its full year results for the year ended 31 May 2017 on Friday 20 October 2017.

Geoffrey Hamilton-Fairley, Chief Executive Officer, and Andrew Millet, Chief Financial Officer, will host a presentation and live conference call for analysts at 9.30am BST on the morning of the results in the Guildhall Room at 85 Gresham Street, London, EC2V 7NQ.

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Broker)

Giles Balleny, Hugh Kingsmill Moore

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com

 

END

 

 

NORKMMGGVLMGNZM